Andes virus infection of lymphatic endothelial cells causes giant cell and enhanced permeability responses that are rapamycin and vascular endothelial growth factor c sensitive

Journal of Virology

Volumn 86, Issue 16, 2012, Pages 8765-8772

  Gavrilovskaya, Irina N ^a   Gorbunova, Elena E ^a   Mackow, Erich R ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 BETA3 INTEGRIN ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

ANDES VIRUS INFECTION; ARTICLE; CELL COUNT; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; ENDOTHELIUM CELL; ENZYME ACTIVATION; GIANT CELL; HANTAVIRUS; HUMAN; HUMAN CELL; LYMPH VESSEL ENDOTHELIUM; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION; VIRUS INFECTION;

ANIMALS; CAPILLARY PERMEABILITY; CELL LINE; ENDOTHELIAL CELLS; GIANT CELLS; HANTAAN VIRUS; HANTAVIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84865087603     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00817-12     Document Type: Article

References (86)

1. Aird WC. 2004. Endothelium as an organ system. Crit. Care Med. 32: S271-S279. doi:10.1097/01.CCM.0000129669.21649.40.
2. Alitalo K, Carmeliet P. 2002. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1:219-227.
3. Avraamides CJ, Garmy-Susini B, Varner JA. 2008. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 8:604-617.
4. Bahram F, Claesson-Welsh L. 2010. VEGF-mediated signal transduction in lymphatic endothelial cells. Pathophysiology 17:253-261.
5. Baluk P, et al. 2007. Functionally specialized junctions between endothelial cells of lymphatic vessels. J. Exp. Med. 204:2349-2362.
6. Berger MM, et al. 2005. Hypoxia impairs systemic endothelial function in individuals prone to high-altitude pulmonary edema. Am. J. Respir. Crit. Care Med. 172:763-767.
7. Borges E, Jan Y, Ruoslahti E. 2000. Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J. Biol. Chem. 275:39867-39873.
8. Breen EC. 2007. VEGF in biological control. J. Cell Biochem. 102:1358-1367.
9. Breslin JW, et al. 2007. Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism. Am. J. Physiol. Heart Circ. Physiol. 293:H709-H718.
10. Breslin JW, Yuan SY, Wu MH. 2007. VEGF-C alters barrier function of cultured lymphatic endothelial cells through a VEGFR-3-dependent mechanism. Lymphat Res. Biol. 5:105-113.
11. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG, Jr. 2003. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4:147-158.
12. Bustamante EA, Levy H, Simpson SQ. 1997. Pleural fluid characteristics in hantavirus pulmonary syndrome. Chest 112:1133-1136.
13. Cam H, Houghton PJ. 2011. Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences. Target Oncol. 6:95-102.
14. Chang B, Crowley M, Campen M, Koster F. 2007. Hantavirus cardiopulmonary syndrome. Semin. Respir. Crit. Care Med. 28:193-200.
15. Christou H, Yoshida A, Arthur V, Morita T, Kourembanas S. 1998. Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 18:768-776.
16. Dehler M, Zessin E, Bartsch P, Mairbaurl H. 2006. Hypoxia causes permeability oedema in the constant-pressure perfused rat lung. Eur. Respir. J. 27:600-606.
17. Dixelius J, et al. 2003. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J. Biol. Chem. 278:40973-40979.
18. Duchin JS, et al. 1994. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N. Engl. J. Med. 330:949-955.
19. Dvorak HF. 2006. Discovery of vascular permeability factor (VPF). Exp. Cell Res. 312:522-526.
20. Dvorak HF, Brown LF, Detmar M, Dvorak AM. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1029-1039.
21. Dvorak HF, et al. 1991. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J. Exp. Med. 174:1275-1278.
22. Enria D, et al. 1996. Hantavirus pulmonary syndrome in Argentina. Possibility of person to person transmission. Medicina 56:709-711.
23. Forsythe JA, et al. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16: 4604-4613.
24. Gavard J. 2009. Breaking the VE-cadherin bonds. FEBS Lett. 583:1-6.
25. Gavard J, Gutkind JS. 2006. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat. Cell Biol. 8:1223-1234.
26. Gavard J, Patel V, Gutkind JS. 2008. Angiopoietin-1 prevents VEGFinduced endothelial permeability by sequestering Src through mDia. Dev. Cell 14:25-36.
27. Gavrilovskaya IN, Brown EJ, Ginsberg MH, Mackow ER. 1999. Cellularentry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins. J. Virol. 73:3951-3959.
28. Gavrilovskaya IN, Gorbunova EE, Mackow ER. 2010. Pathogenic hantaviruses direct the adherence of quiescent platelets to infected endothelial cells. J. Virol. 84:4832-4839.
29. Gavrilovskaya IN, Gorbunova EE, Mackow NA, Mackow ER. 2008. Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphingosine 1-phosphate inhibit hantavirus-directed permeability. J. Virol. 82:5797-5806.
30. Gavrilovskaya IN, Peresleni T, Geimonen E, Mackow ER. 2002. Pathogenic hantaviruses selectively inhibit beta3 integrin directed endothelial cell migration. Arch. Virol. 147:1913-1931.
31. Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER. 1998. β3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc. Natl. Acad. Sci. U. S. A. 95:7074-7079.
32. Geimonen E, et al. 2002. Pathogenic and nonpathogenic hantaviruses differentially regulate endothelial cell responses. Proc. Natl. Acad. Sci. U. S. A. 99:13837-13842.
33. Goldman J, et al. 2007. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. FASEB J. 21:1003-1012.
34. Gorbunova E, Gavrilovskaya IN, Mackow ER. 2010. Pathogenic hantaviruses Andes virus and Hantaan virus induce adherens junction disassembly by directing vascular endothelial cadherin internalization in human endothelial cells. J. Virol. 84:7405-7411.
35. Gorbunova EE, Gavrilovskaya IN, Pepini T, Mackow ER. 2011. VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability. J. Virol. 85:2296-2303.
36. Hallin GW, et al. 1996. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit. Care Med. 24:252-258.
37. Hammerbeck CD, Hooper JW. 2011. T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome. J. Virol. 85:9929-9944.
38. Hanaoka M, et al. 2003. Vascular endothelial growth factor in patients with high-altitude pulmonary edema. J. Appl. Physiol. 94:1836-1840.
39. Hjelle B, et al. 1994. A novel hantavirus associated with an outbreak of fatal respiratory disease in the southwestern United States: evolutionary relationships to known hantaviruses. J. Virol. 68:592-596.
40. Hooper JW, Larsen T, Custer DM, Schmaljohn CS. 2001. A lethal disease model for hantavirus pulmonary syndrome. Virology 289:6-14.
41. Huber S, et al. 2007. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int. 71:771-777.
42. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. 2002. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J. 16:771-780.
43. Ikeda H, et al. 2011. Increased Akt-mTOR signaling in lung epithelium is associated with respiratory distress syndrome in mice. Mol. Cell. Biol. 31:1054-1065.
44. Karkkainen MJ, et al. 2000. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet. 25:153-159.
45. Kilpatrick ED, et al. 2004. Role of specific CD8 T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. J. Immunol. 172:3297-3304.
46. Kobayashi S, et al. 2007. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci. 98:726-733.
47. Koster F, et al. 2001. Rapid presumptive diagnosis of hantavirus cardiopulmonary syndrome by peripheral blood smear review. Am. J. Clin. Pathol. 116:665-672.
48. Lähdevirta J, Enger E, Hunderi OH, Traavik T, Lee HW. 1982. Hantaan virus is related to hemorrhagic fever with renal syndrome in Norway. Lancet ii:606.
49. Lampugnani MG, Orsenigo F, Gagliani MC, Tacchetti C, Dejana E. 2006. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J. Cell Biol. 174:593-604.
50. Land SC, Tee AR. 2007. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J. Biol. Chem. 282:20534-20543.
51. Lee HW. 1982. Hemorrhagic fever with renal syndrome (HFRS). Scand. J. Infect. Dis. Suppl. 36:82-85.
52. Lohela M, Bry M, Tammela T, Alitalo K. 2009. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 21:154-165.
53. López N, Padula P, Rossi C, Lazaro ME, Franze-Fernandez MT. 1996. Genetic identification of a new hantavirus causing severe pulmonary syndrome in Argentina. Virology 220:223-226.
54. Major P. 2011. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. Aging 3:189-191.
55. Manalo DJ, et al. 2005. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105:659-669.
56. Matthys VS, Gorbunova EE, Gavrilovskaya IN, Mackow ER. 2010. Andes virus recognition of human and Syrian hamster beta3 integrins is determined by an L33P substitution in the PSI domain. J. Virol. 84:352-360.
57. Mukhopadhyay D, et al. 1995. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375:577-581.
58. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. 2008. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 11:109-119.
59. Nolte KB, et al. 1995. Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Hum. Pathology 26:110-120.
60. Ohmi K, Yamashita S, Hashimoto Y, Nonomura Y. 1993. Induction of giant endothelial cells in culture by K-252a, a protein kinase inhibitor. Jpn. J. Pharmacol. 63:195-202.
61. Paddenberg R, et al. 2007. Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respir. Res. 8:15.
62. Padula PJ, et al. 1998. Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology 241:323-330.
63. Pepini T, Gorbunova EE, Gavrilovskaya I, Mackow JE, Mackow ER. 2010. Andes virus regulation of cellular microRNAs contributes to hantavirus-induced endothelial cell permeability. J. Virol. 84:11929-11936.
64. Pham I, et al. 2002. Hypoxia upregulates VEGF expression in alveolar epithelial cells in vitro and in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol. 283:L1133-L1142.
65. Raymond T, Gorbunova E, Gavrilovskaya IN, Mackow ER. 2005. Pathogenic hantaviruses bind plexin-semaphorin-integrin domains present at the apex of inactive, bent alphavbeta3 integrin conformers. Proc. Natl. Acad. Sci. U. S. A. 102:1163-1168.
66. Reynolds AR, et al. 2004. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res. 64:8643-8650.
67. Reynolds LE, et al. 2002. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat. Med. 8:27-34.
68. Robinson SD, Reynolds LE, Wyder L, Hicklin DJ, Hodivala-Dilke KM. 2004. Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arterioscler. Thromb. Vasc. Biol. 24:2108-2114.
69. Ruvinsky I, Meyuhas O. 2006. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem. Sci. 31:342-348.
70. Safronetz D, Haddock E, Feldmann F, Ebihara H, Feldmann H. 2011. In vitro and in vivo activity of ribavirin against Andes virus infection. PLoS One 6:e23560. doi:10.1371/journal.pone.0023560.
71. Schittenhelm MM, et al. 2006. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 66:473-481.
72. Schmaljohn C, Hjelle B. 1997. Hantaviruses: a global disease problem. Emerg. Infect. Dis. 3:95-104.
73. Schraufnagel DE. 2010. Lung lymphatic anatomy and correlates. Pathophysiology 17:337-343.
74. Shrivastava-Ranjan P, Rollin PE, Spiropoulou CF. 2010. Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. J. Virol. 84:11227-11234.
75. Sillaber C, et al. 2009. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140mg daily. Eur. J. Clin. Invest. 39:1098-1109.
76. Stenmark KR, Fagan KA, Frid MG. 2006. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ. Res. 99: 675-691.
77. Tang N, et al. 2004. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6:485-495.
78. Thurston G, et al. 2000. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 6:460-463.
79. Toro J, et al. 1998. An outbreak of hantavirus pulmonary syndrome, Chile, 1997. Emerg. Infect. Dis. 4:687-694.
80. van Hinsbergh VW, van Nieuw Amerongen GP. 2002. Endothelial hyperpermeability in vascular leakage. Vascul. Pharmacol. 39:171-172.
81. Wahl-Jensen V, et al. 2007. Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamsters. J. Virol. 81:7449-7462.
82. Weis SM, Cheresh DA. 2012. αv integrins in angiogenesis and cancer. Cold Spring Harb. Perspect. Med. 1:a006478.
83. Wouters BG, Koritzinsky M. 2008. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer. 8:851-864.
84. Xue Q, et al. 2009. Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arterioscler. Thromb. Vasc. Biol. 29:1172-1178.
85. Yanagihara R, Silverman DJ. 1990. Experimental infection of human vascular endothelial cells by pathogenic and nonpathogenic hantaviruses. Arch. Virol. 111:281-286.
86. Zaki S, et al. 1995. Hantavirus pulmonary syndrome: pathogenesis of an emerging infectious disease. Am. J. Pathol. 146:552-579.